OncoMatch/Clinical Trials/NCT04371224
NaliCap (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer
Is NCT04371224 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Irinotecan Liposomal and Capecitabine for pancreatic cancer.
Treatment: Irinotecan Liposomal · Capecitabine · 5-fluorouracil · Leucovorin — This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: gemcitabine (gemcitabine) — advanced pancreatic cancer
Gemcitabine-pretreated for advanced pancreatic cancer
Cannot have received: investigational product
Participation in another clinical study with an investigational product (IP) during the last 3 weeks
Cannot have received: anti-cancer therapy
Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify